Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Phenazopyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | HBB | P68871 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.96 |
| ▸ | USP2 | O75604 | 1/20 | 0.96 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.96 |
| ▸ | DRD2 | P14416 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenazopyridine SCHEMBL14687482 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL29392321 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL26499 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL28796595 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL19357 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL301672 | 0.98 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL5973732 | 0.98 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL302506 | 0.98 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL6661856 | 0.98 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL9151827 | 0.98 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252154-B1 | METHOD FOR MINIMIZING THE CYTOTOXICITY OF THE EFFECTIVE AGENT IN A COMPOSITION THAT IS ADMINISTERED TO A MAMMAL OR GETS INTO CONTACT WITH A MAMMAL | OY GRANULA AB LTD (FI) | 2016-01-27 | — | — | EP | claimed |
| US-8496974-B2 | Method for preparing a composition comprising a compound mixture and a carrier agent | OY GRANULA AB LTD (FI) | 2013-07-30 | — | — | US | claimed |
| US-8431170-B2 | Antimicrobial composition with low cytotoxicity | OY GRANULA AB LTD. (FI) | 2013-04-30 | — | — | US | claimed |
| EP-2252154-A2 | METHOD FOR MINIMIZING THE CYTOTOXICITY OF THE EFFECTIVE AGENT IN A COMPOSITION THAT IS ADMINISTERED TO A MAMMAL OR GETS INTO CONTACT WITH A MAMMAL | Oy Granula AB LTD (FI) | 2010-11-24 | — | — | EP | claimed |
| EP-2252155-A2 | METHOD FOR MINIMIZING THE CYTOTOXICITY OF THE EFFECTIVE AGENT INHIBITING THE GROWTH OF MICRO-ORGANISMS AND FOR MAXIMIZING THE EFFECT | Oy Granula AB LTD (FI) | 2010-11-24 | — | — | EP | claimed |
| US-20100129304-A1 | METHOD FOR PREPARING A COMPOSITION COMPRISING A COMPOUND MIXTURE AND A CARRIER AGENT | OY GRANULA AB LTD (FI) | 2010-05-27 | — | — | US | claimed |
| US-20100129302-A1 | ANTIMICROBIAL COMPOSITION WITH LOW CYTOTOXICITY | OY GRANULA AB LTD (FI) | 2010-05-27 | — | — | US | claimed |
| WO-2009101261-A2 | METHOD FOR MINIMIZING THE CYTOTOXICITY OF THE EFFECTIVE AGENT IN A COMPOSITION THAT IS ADMINISTERED TO A MAMMAL OR GETS INTO CONTACT WITH A MAMMAL | OY GRANULA AB LTD (FI) | 2009-08-20 | — | — | WO | claimed |
| WO-2009101262-A2 | METHOD FOR MINIMIZING THE CYTOTOXICITY OF THE EFFECTIVE AGENT INHIBITING THE GROWTH OF MICRO-ORGANISMS AND FOR MAXIMIZING THE EFFECT | OY GRANULA AB LTD (FI) | 2009-08-20 | — | — | WO | claimed |
| US-6046352-A | Preparation of 4-cyano-4'-hydroxybiphenyl | SOCIETE D'EXPANSION SCIENTIFIQUE EXPANSIA (FR) | 2000-04-04 | — | — | US | claimed |
| EP-0242415-B1 | LAYERED TEXTILE WOUND DRESSING | Karl Otto Braun KG (DE) | 1989-01-25 | — | — | EP | claimed |
| EP-0079038-B1 | HIGHLY VISCOUS POLYSACCHARIDES AND PROCESS FOR THE PREPARATION OF SAID POLYSACCHARIDES | Nakano Vinegar Co., Ltd. (JP) | 1986-05-21 | — | — | EP | claimed |
| US-20240115709-A1 | ASSEMBLY OF ORGANIC SUPRAMOLECULAR VESSELS FOR CONTROLLED DRUG RELEASE | NOBLE PANACEA LABS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| EP-4297790-A1 | ASSEMBLY OF ORGANIC SUPRAMOLECULAR VESSELS FOR CONTROLLED DRUG RELEASE | Noble Panacea Labs, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2022182945-A1 | ASSEMBLY OF ORGANIC SUPRAMOLECULAR VESSELS FOR CONTROLLED DRUG RELEASE | NOBLE PANACEA LABS, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
| WO-2022092522-A1 | ORAL COMPOSITION FOR AMELIORATING BAD BREATH | 주식회사 에코월드팜 | 2022-05-05 | — | — | WO | disclosed |
| EP-0173516-A2 | (Fused)benz(thio)amides | ONO PHARMACEUTICAL CO., LTD. (JP) | 1986-03-05 | — | — | EP | disclosed |
| EP-0121730-A2 | Crystalline aluminosilicate and process for the production thereof | RESEARCH ASSOCIATION FOR PETROLEUM ALTERNATIVES DEVELOPMENT (JP) | 1984-10-17 | — | — | EP | disclosed |
| US-4108882-A | QUATERNARY AMMONIUM HALIDE CATALYST | DOW CORNING CORPORATION (US) | 1978-08-22 | — | — | US | disclosed |
| US-4103082-A | ANTIMICROBIAL | SUAMI T | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129302-A1 | ANTIMICROBIAL COMPOSITION WITH LOW CYTOTOXICITY | CUTA, LCT, PYCARD | MAPT 567/4885MEN1 4643/4885KMT2A 976/4885 |
| US-20100129304-A1 | METHOD FOR PREPARING A COMPOSITION COMPRISING A COMPOUND MIXTURE AND A CARRIER AGENT | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, BAK1, PMAIP1 | MAPT 564/4885MEN1 3431/4885KMT2A 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.